These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33387018)

  • 21. Inositol 1,4,5-trisphosphate receptor type 2 is associated with the bone-vessel axis in chronic kidney disease-mineral bone disorder.
    Xiao Q; Tang Y; Luo H; Chen S; Tang Q; Chen R; Xiong L; Xiao J; Hong D; Wang L; Li G; Li Y
    Ren Fail; 2023 Dec; 45(1):2162419. PubMed ID: 36645057
    [No Abstract]   [Full Text] [Related]  

  • 22. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. News on biomarkers in CKD-MBD.
    Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
    Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort.
    Reimer KC; Nadal J; Meiselbach H; Schmid M; Schultheiss UT; Kotsis F; Stockmann H; Friedrich N; Nauck M; Krane V; Eckardt KU; Schneider MP; Kramann R; Floege J; Saritas T;
    Bone Res; 2023 Oct; 11(1):52. PubMed ID: 37857629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway.
    Shen J; Liu Y; Wang Q; Chen H; Hu Y; Guo X; Liu X; Li Y
    J Ethnopharmacol; 2023 Oct; 314():116590. PubMed ID: 37207881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skeletal effects and growth in children with chronic kidney disease: a 5-year prospective study.
    Swolin-Eide D; Hansson S; Magnusson P
    J Bone Miner Metab; 2013 May; 31(3):322-8. PubMed ID: 23224949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.
    Magagnoli L; Cozzolino M; Caskey FJ; Evans M; Torino C; Porto G; Szymczak M; Krajewska M; Drechsler C; Stenvinkel P; Pippias M; Dekker FW; de Rooij ENM; Wanner C; Chesnaye NC; Jager KJ;
    Nephrol Dial Transplant; 2023 Oct; 38(11):2562-2575. PubMed ID: 37230954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
    Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
    Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.
    Sprague SM; Bellorin-Font E; Jorgetti V; Carvalho AB; Malluche HH; Ferreira A; D'Haese PC; Drüeke TB; Du H; Manley T; Rojas E; Moe SM
    Am J Kidney Dis; 2016 Apr; 67(4):559-66. PubMed ID: 26321176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
    Pazianas M; Miller PD
    Am J Kidney Dis; 2021 Oct; 78(4):582-589. PubMed ID: 33774081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD-MBD in maintenance hemodialysis patients.
    Jia XY; Wei K; Chen J; Xi LH; Kong XL; Wei Y; Wang L; Wang ZS; Liu YP; Liang LM; Xu DM
    J Bone Miner Metab; 2021 Nov; 39(6):1058-1065. PubMed ID: 34392464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Regression analysis of serum bone metabolic markers and traditional Chinese medicine syndromes in patients with CKD-MBD].
    Yang HM; Meng XJ; Wu W; Liu YL; Zhai XJ
    Zhongguo Zhong Yao Za Zhi; 2017 Oct; 42(20):4027-4034. PubMed ID: 29243442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
    Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alkaline Phosphatase, iPTH and Bone Turnover Markers in Chinese Advanced Chronic Kidney Disease Patients.
    Liu Y; He Q
    Clin Lab; 2015; 61(7):839-43. PubMed ID: 26299086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crosstalk between kidney and bone: insights from CKD-MBD.
    Suzuki K; Soeda K; Komaba H
    J Bone Miner Metab; 2024 Jul; 42(4):463-469. PubMed ID: 39060498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of calcifediol supplementation on markers of chronic kidney disease-mineral and bone disorder in dogs with chronic kidney disease.
    Parker VJ; Rudinsky AJ; Benedict JA; Beizaei A; Chew DJ
    J Vet Intern Med; 2020 Nov; 34(6):2497-2506. PubMed ID: 33128421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
    Yamada S; Nakano T
    J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.